Avalo Therapeutics, Inc. $AVTX Shares Bought by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC grew its position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 27.6% during the first quarter, Holdings Channel.com reports. The firm owned 1,340,840 shares of the company’s stock after acquiring an additional 289,786 shares during the period. Affinity Asset Advisors LLC’s holdings in Avalo Therapeutics were worth $20,019,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. UBS Group AG grew its holdings in shares of Avalo Therapeutics by 956.9% during the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock worth $8,677,000 after purchasing an additional 432,608 shares during the last quarter. Moody Aldrich Partners LLC purchased a new position in Avalo Therapeutics in the fourth quarter worth $2,419,000. Nan Fung Trinity HK Ltd. acquired a new stake in shares of Avalo Therapeutics during the 4th quarter valued at approximately $3,432,000. Jennison Associates LLC acquired a new stake in Avalo Therapeutics in the fourth quarter valued at $8,637,000. Finally, 683 Capital Management LLC purchased a new position in Avalo Therapeutics during the 4th quarter valued at about $1,032,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Insider Transactions at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the transaction, the insider directly owned 51,776 shares of the company’s stock, valued at $931,968. The trade was a 2.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,458 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total value of $110,715.22. Following the sale, the chief financial officer owned 8,880 shares of the company’s stock, valued at $116,239.20. The trade was a 48.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 93,428 shares of company stock worth $1,762,722 in the last three months. 4.46% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday. Piper Sandler reissued an “overweight” rating and issued a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Weiss Ratings downgraded Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Mizuho lifted their price objective on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Finally, BTIG Research reiterated a “buy” rating and issued a $58.00 target price on shares of Avalo Therapeutics in a research note on Tuesday, June 16th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Avalo Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $45.80.

Avalo Therapeutics Stock Up 3.8%

AVTX stock opened at $18.44 on Friday. The company has a market cap of $975.48 million, a price-to-earnings ratio of -3.38 and a beta of 0.78. The business has a fifty day simple moving average of $16.74 and a 200-day simple moving average of $16.12. Avalo Therapeutics, Inc. has a 52 week low of $6.21 and a 52 week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. As a group, analysts expect that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.